Bluebirdbio stock.

Nov 28, 2023 · Buy or Hold candidate since Nov 15, 2023 Gain 16.72% PDF. No changes to the price of bluebird bio stock on the last trading day (Tuesday, 28th Nov 2023). During the last trading day the stock fluctuated 5.19% from a day low at $3.66 to a day high of $3.85. The price has risen in 6 of the last 10 days and is up by 27.15% over the past 2 weeks. Shares of Bluebird Bio ( BLUE -3.00%) were plunging 22.3% as of 10:41 a.m. ET on Monday. The big drop came after the company announced that the Food and Drug Administration (FDA) placed its ...What happened. Shares of gene therapy company Bluebird Bio ( BLUE -6.90%) fell by 10.7% through the first four full days of trading this week, according to data provided by S&P Global Market ...Nov 4, 2021 · November 04, 2021 07:00 AM Eastern Daylight Time. CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- bluebird bio, Inc. (NASDAQ: BLUE) today announced the company has completed the tax-free spin-off of its ... SOMERVILLE, Mass.--(BUSINESS WIRE)--Jan. 18, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced that it has commenced an underwritten public offering of 20,000,000 shares of its common stock. bluebird also intends to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its …

Bluebird Bio Inc (NASDAQ: BLUE) shares are trading lower Monday. The stock initially surged in premarket trading following the U.S. Food and Drug Administration's accelerated approval of ...View bluebird bio, Inc BLUE investment & stock information. Get the latest bluebird bio, Inc BLUE detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

According to 9 stock analysts, the average 12-month stock price forecast for bluebird bio stock is $7.91, which predicts an increase of 107.07%. The lowest target is $3.00 and the highest is $13. On average, analysts rate bluebird bio stock as a buy.

Many gene-editing stocks have taken a hit in the past year, but analysts at Strategic Market Research still expect the genome-editing market to grow 17.3% annually and reach $21.3 billion by 2030.Mar 30, 2023 · What happened. Shares of the gene therapy pioneer Bluebird Bio ( BLUE -1.04%) have been under heavy pressure this week. The biotech's stock dropped by a noteworthy 28.8% during the first three and ... We would like to show you a description here but the site won’t allow us.Bluebird Bio (BLUE) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.72. ... bluebird bio, Inc. (BLUE) : Free Stock Analysis Report. Cardiff ...

Get bluebird bio Inc (BLUE.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments

bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock. SOMERVILLE, Mass.-- (BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a publi... 11 months ago - Business Wire.

View bluebird bio, Inc BLUE investment & stock information. Get the latest bluebird bio, Inc BLUE detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Who is on bluebird bio's Insider Roster? The list of insiders at bluebird bio includes Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Nick Leschly, Richard A Colvin, Thomas J Klima, and William D Baird III. Learn more on insiders at BLUE.Find the latest 2seventy bio, Inc. (TSVT) stock quote, history, news and other vital information to help you with your stock trading and investing.bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel ...bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock. SOMERVILLE, Mass.-- (BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a publi... 11 months ago - Business Wire.Shares of Bluebird Bio ( BLUE -0.78%) were crashing 23.3% lower as of 12:18 p.m. EDT on Monday. The big decline came after the company announced two negative developments in its second-quarter ...

Bluebird Bio ( BLUE 2.64%) had quite a ride with their stock on Tuesday. Following the gene-editing specialist's release of its latest quarterly results, its shares climbed to a more than 7% gain ...Here are three top biotech stocks with major catalysts in December. Editas Medicine ( EDIT ): EDIT will release key clinical data on its sickle cell treatment on Dec. 11. Bluebird Bio ( BLUE ): It ...The past three years have been a southbound roller coaster for Bluebird Bio (BLUE 8.43%). The small-cap biotech encountered a series of headwinds, losing 90% of its value.The past three years have been a southbound roller coaster for Bluebird Bio (BLUE 8.43%). The small-cap biotech encountered a series of headwinds, losing 90% of its value.Overview News bluebird bio Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-0.74 Market Cap $425.32 M Shares …November 04, 2021 07:00 AM Eastern Daylight Time. CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- bluebird bio, Inc. (NASDAQ: BLUE) today announced the company has completed the tax-free spin-off of its ...bluebird bio, Inc. Common Stock (BLUE) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.

bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How. bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its approved therapies.

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel ...Stock Price Forecast. According to 9 stock analysts, the average 12-month stock price forecast for bluebird bio stock is $7.91, which predicts an increase of 108.71%. The lowest target is $3.00 and the highest is $13. On average, analysts rate bluebird bio stock as a buy.CRISPR Therapeutics (CRSP-0.74%) and Bluebird Bio (BLUE 2.64%) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12 ...8 thg 5, 2019 ... ...more. Alliance for Regenerative Medicine. 6.53K. Subscribe. 6.53K subscribers. 4. Share. Save. Report. Comments. thumbnail-image. Add a ...10 giờ trước ... InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest ...According to 9 stock analysts, the average 12-month stock price forecast for bluebird bio stock is $7.91, which predicts an increase of 107.07%. The lowest target is $3.00 and the highest is $13. On average, analysts rate bluebird bio stock as a buy.bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel ...

The current price bluebird bio (BLUE) is trading at is $3.87, which is out of the analyst’s predicted range. Browse analyst ratings and price targets on all stocks. Popular Channels

10 giờ trước ... InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest ...

The last 12 months haven't been kind to the likes of gene editing stocks like CRISPR Therapeutics (CRSP 2.88%) and Bluebird Bio (BLUE 11.52%). Whereas CRISPR's shares fell by 31%, Bluebird's are ...Oct 20, 2021 · Key Points. Bluebird Bio's shares have dropped like a rock in recent years, and its new price tag makes the stock look more like a buy. The biotech boasts an exciting lineup of gene therapies for ... Here's why. BLUE data by YCharts. 1. Bluebird Bio. To say that Bluebird Bio has lagged the market in the past year would be an understatement. The gene-editing specialist has lost over 70% of its [email protected]. Investor Contacts. Courtney O’Leary. Investor Relations (978) 621-7347. [email protected]. stock quote stock sub menu. Stock ... 10 thg 3, 2021 ... BLUE Stock Pops On Gene Therapy Analysis ... On the stock market today, BLUE stock jumped 8.1% to 32.48. Bluebird uses an empty virus to deliver ...1. Bluebird Bio. Bluebird Bio is a biotech that seeks to develop gene-editing treatments for rare illnesses. Some of the company's efforts came to fruition this year as it finally earned U.S ...Get the latest bluebird bio, Inc. (BLUE) stock news and headlines to help you in your trading and investing decisions. Bluebird bio Inc () Stock Market info Recommendations: Buy or sell Bluebird bio stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Bluebird bio share forecasts, stock quote and buy / sell signals below.According to present data Bluebird bio's BLUE shares and potentially its market environment have been in bearish …Amgen, for instance, is one of the largest biotech companies in the U.S., with a market cap of more than $100 billion. It makes dozens of Food and Drug Administration-approved drugs, including ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--Jan. 18, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced that it has commenced an underwritten public offering of 20,000,000 shares of its common stock. bluebird also intends to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its …Specifically, the biotech's stock is down by 11% as of 12:56 p.m. ET on Monday. Bluebird's shares are retreating today in response to two key issues: First, the company's 2021 fourth-quarter and ...Bluebird Bio has a market capitalization of around $425 million at the moment, so this small-cap biotech stock could see a significant increase in its share …Instagram:https://instagram. nyse mthspacex stocksbest airlines to invest inruseell 1000 Key Points. Bluebird Bio's shares have dropped like a rock in recent years, and its new price tag makes the stock look more like a buy. The biotech boasts an exciting lineup of gene therapies for ... best medigap plans in pabest health insurance plans in colorado Foundational software QNX RTOS 8. QNX in cars increased by 9% yoy according to JC on previous CC's; so what is the likelihood that in 2023 that we go from 235 million to over 255 million or even more from 9% in 2024. Note that QNX is in both ICE and EV's. Also, that IOT at the end of last fiscal year in Feb 2023 had a backlog of $640 million. best apps for forex trading BLUE Stock Overview · Revenue is forecast to grow 47.03% per year · Earnings have grown 18.9% per year over the past 5 years · Has less than 1 year of cash ...bluebird bio, Inc. (BLUE) Stock Price, Quote & News - Stock Analysis 3.89 +0.10 (2.64%) At close: Nov 24, 2023, 1:00 PM 3.92 +0.03 (0.77%) After-hours: Nov 24, …Get bluebird bio Inc (BLUE.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments